Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Herpes Labialis: full-pipeline trial registry
1 of 7 indexed Herpes Labialis trials are currently recruiting.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 1 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Herpes Labialis: 7 US clinical trials tracked, 1 recruiting.
Herpes Labialis is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Medivir, running 1 of these trials.
Enrollment posture brief
Registry condition herpes-labialis
OPEN 1 | RECR 14% | LATE 3 | EARLY 3 | RANK #2497 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adverse Drug Events (14% recruiting · 7 trials)
Herpes Labialis lists 1 open slots (14% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Herpes Labialis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Herpes Labialis is recruiting below its size-band peers.
1 of 7 indexed trials (14.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Herpes Labialis trials is spread across many organizations.
Medivir accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Herpes Labialis enrolment sits around 1,000 participants.
Median target enrolment is 1,000 among the 7 trials that report a genuine target (sentinel values excluded). 2 of those (28.6%) plan for fewer than 100 participants.
-
Herpes Labialis research is mostly interventional.
6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Viral Infections in Healthy and Immunocompromised Hosts
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01306084
Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis
Transport Pharmaceuticals
NCT00230867
Phase 3 Clinical Study for the Treatment of Cold Sore
Valerio Therapeutics
NCT00769314
Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis
Medivir
NCT00361881
Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis
University of Utah
NCT00297011
Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old
Meda Pharmaceuticals
NCT01574612
Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis
Novartis Pharmaceuticals
NCT00878072
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Herpes Labialis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Herpes Labialis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Herpes Labialis page
7 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Herpes Labialis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Medivir sponsors the most Herpes Labialis trials on record, review their full trial history before evaluating a specific study. See Medivir's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Herpes Labialis condition card totals 7 registered trials; most-linked intervention acyclovir in ME-609 vehicle; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.